Background: Trichinellosis is a food borne widespread zoonotic pathogen distributed all over the world, Trichnella spiralis (T. spiralis) is the most popular species to cause the disease. Medications such as anthelmintics (mebendazole or albendazole) and glucocorticosteroids are used to treat the condition. Objective: This review article aimed toassess the updated treatment modalities of trichinellosis. Methods: We searched PubMed, Google Scholar, and Science Direct for information on Trichinellosis with treatment. However, only the most current or comprehensive study from May 2006 to May 2022 was considered. The authors also assessed references from pertinent literature. Documents in languages other than English have been disregarded since there aren't enough resources for translation. Unpublished manuscripts, oral presentations, conference abstracts, and dissertations were examples of papers that weren't considered to be serious scientific research. Conclusion: Trichinellosis treatment presents a number of challenges. During the time of intestinal invasion, anthelmintics are required (i.e., less than 1 week after infection). Treatment is typically initiated at the earliest stages of larval development in muscle cells, but this is rarely attainable. Efforts to improve Trichinellosis treatments by the use of pharmaceuticals are the target. Mebendazole and albendazole are the most often used medications for treating trichinellosis. Pyrantel is safe for usage by pregnant women and children. The bacterium Streptomyces avermitilis is responsible for producing ivermectin, which is then classified as a macrocyclic lactone.